Amphivena Announces Upcoming Oral Presentation at AACR Virtual Annual Meeting II

South San Francisco, CA – June 17, 2020 — Amphivena Therapeutics, a clinical-stage immuno-oncology company focused on developing immuno-therapeutics that restore anti-cancer immunity, today announced that it will present translational data for its lead clinical candidate, AMV564, a bivalent T-cell engager, at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II being held June 22 – 24.

The oral presentation (#5699) entitled, “AMV564, a bivalent, bispecific T-cell engager, depletes myeloid-derived suppressor cells and activates T cells in cancer patients” will be presented by the Company’s chief scientific officer, Victoria Smith, Ph.D..

Details of the Presentation:

  • Session Title: Novel Immunotherapies and Mechanisms
  • Session Start Date/Time: Tuesday, June 23, 2020, 9:00 – 11:00 AM ET
  • Abstract Number: 4630

The full abstract is available now on the AACR Annual Meeting and Amphivena websites, and the video presentation will be available following the virtual meeting.

About Amphivena Therapeutics, Inc.
Amphivena Therapeutics, Inc. is a privately held, clinical-stage, immuno-oncology company based in South San Francisco, CA that is developing a novel platform of dual-action biologics to selectively relieve immune suppression and drive T-cell activation/polarization, to restore anti-cancer immunity in patients. The company’s lead therapeutic candidate, AMV564, induces selective T-cell mediated killing of myeloid derived suppressor cells (MDSC), known to be associated with immune suppression and poor outcomes to immunotherapy. In parallel, it drives T cell activation. AMV564 has exhibited an excellent clinical safety profile and combinability with checkpoint inhibition and represents a unique opportunity to bring new treatment options to cancer patients underserved by immunotherapy.

Amphivena has raised $88.5 M to date in Series A, B and C venture financings led by NanoDimension, Qiming Venture Partners USA, MPM Capital and funds managed by Tekla Capital Management LLC.

Alicia Chung, Corporate Development
+1 650-499-3178